Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil plus bevacizumab as second-line maintenance in advanced colorectal cancer
ChiCTR2600124199Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal adenocarcinoma, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Progression-free survival. Started May 2026; status: recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600124199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124199.